TABLE 2.

Comparisons of All-Cause Health Care Costs After PSM

PPPM Costs	Apixaban Cohort n = 7,607	Warfarin Cohort n = 7,607		Apixaban Cohort n = 4,129	Dabigatran Cohort n = 4,129		Apixaban Cohort n = 11,284	Rivaroxaban Cohort n = 11,284
	Marginal Effecta ($)	Marginal Effect ($)	P Value	Marginal Effect ($)	Marginal Effect ($)	P Value	Marginal Effect ($)	Marginal Effect ($)	P Value
All-cause outpatient medical costs	1,206	1,157	0.341	1,222	1,236	0.888	1,174	1,217	0.284
All-cause inpatient medical costs	711	1,092	0.002	565	781	0.034	658	939	< 0.001
All-cause medical costs	1,917	2,249	0.026	1,787	2,018	0.143	1,832	2,156	< 0.001
Pharmacy costs	360	248	< 0.001	356	354	0.904	368	390	0.032
All-cause health care costs	2,277	2,498	0.148	2,143	2,372	0.150	2,200	2,546	< 0.001

^aMarginal effect measures the marginal contribution of each variable (in this case, each oral anticoagulant drug in the matched pairs) on the scale of the linear predictor.

PPPM = per patient per month; PSM = propensity score matching.